Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma.

A polymorphism in the complement component C1qA correlates with prolonged response following rituximab therapy of follicular lymphoma. Clin Cancer Res. 2008 Oct 15; 14(20):6697-703.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.